-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shisi Pharmaceutical Group Repeats as a Top 25 Hong Kong Stock Market Pharmaceutical Company
Category:
发布时间：2024-11-20
【概要描述】
On November 11, the highly anticipated 2024 Hong Kong Listed Companies Development Summit and the 11th “Top 100 Hong Kong Stocks” Awards Ceremony kicked off in grand style at the Hong Kong Convention and Exhibition Centre. During the event, the main “Top 100 Hong Kong Stocks” ranking was officially unveiled, along with 15 sub-rankings spanning a wide range of sectors and four special individual awards. Shisi Pharmaceutical Group was once again named among the top 25 in the pharmaceutical sector, marking its second consecutive year on this prestigious list.
On November 11, the highly anticipated 2024 Hong Kong Listed Companies Development Summit and the 11th “Top 100 Hong Kong Stocks” Awards Ceremony kicked off in grand style at the Hong Kong Convention and Exhibition Centre. During the event, the main “Top 100 Hong Kong Stocks” ranking was officially unveiled, along with 15 sub-rankings spanning a wide range of sectors and four special individual awards. Shisi Pharmaceutical Group was once again named among the top 25 in the pharmaceutical sector, marking its second consecutive year on this prestigious list.
As a large enterprise specializing in the R&D, production, and operations of chemical pharmaceutical preparations, active pharmaceutical ingredients, and pharmaceutical packaging materials, Shisi Pharmaceutical Group has, in recent years, been driven by innovation. While actively building an integrated, high-performance ecosystem for “APIs plus formulations,” the company has accelerated its digital transformation and promoted smart manufacturing, with a strong focus on elevating the industry’s development toward greater sophistication, intelligence, sustainability, and integration. Through these efforts, Shisi Pharmaceutical has continuously cultivated new drivers of productivity, steadily expanded the market influence of its flagship products, and advanced high-quality development to a new level—earning widespread attention from both the product and capital markets.
According to reports, the “Top 100 Hong Kong Stocks” ranking is organized by the Top 100 Hong Kong Stocks Research Center, co-organized by Caihua News Agency and Futu AnYi, and supported by media organizations such as the Ta Kung Wen Hui Financial Public Relations Group in Hong Kong. The selection process for the “Top 100 Hong Kong Stocks” and its sub-rankings rigorously evaluates companies across five key dimensions: revenue, total market capitalization, net profit after tax, return on equity, and total return. The initiative has become a crucial platform for investors to assess the Hong Kong stock market and for companies to showcase their brand value, earning recognition as one of the benchmark indicators of value and a leading barometer of investment trends in the Hong Kong capital market.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091